



European Directorate for the
Quality of Medicines & HealthCare

Certification of Substances Division



Certificate of suitability No. R0-CEP 2009-050-Rev 00

1 *Name of the substance:*
2 **CHOLECALCIFEROL**

3 *Name of holder:*
4 **DSM NUTRITIONAL PRODUCTS LTD.**
5 Wurmisweg 576
6 Switzerland-4303 Kaiseraugst

7 *Site(s) of production:*
8 **DSM NUTRITIONAL PRODUCTS FRANCE SAS**
9 1 Boulevard D' Alsace
10 France-68128 Village-Neuf

11 After examination of the information provided on the manufacturing method and
12 subsequent processes (including purification) for this substance on the site(s) of
13 production mentioned above, we certify that the quality of the substance is suitably
14 controlled by the current version of the monograph **CHOLECALCIFEROL** no. 72 of the
15 European Pharmacopoeia, current edition including supplements, only if it is
16 supplemented by the test(s) mentioned below, based on the analytical procedure(s)
17 given in annex.

18 – Test for residual solvents by gas chromatography (Annex 1)
19 Methyl formate not more than 1000 ppm

20 In the last steps of the synthesis water is used as solvent.

21 After examination of the information provided on the origin of raw material(s) and type of
22 tissue(s) used and on the manufacturing process for this substance on the site(s) of
23 production mentioned above, we certify that the substance **CHOLECALCIFEROL**
24 meets the criteria described in the current version of the monograph Products with risk
25 of transmitting agents of animal spongiform encephalopathies no. 1483 of the European
26 Pharmacopoeia, current edition including supplements.

27 – nature of animal tissues used in manufacture: Sheep wool

28 The submitted dossier must be updated after any significant change that may alter the
29 quality, safety or efficacy of the substance.

Address: 7, allée Kastner, CS 30026 - F - 67081 Strasbourg (France)
Telephone: 33 (0) 3 88 41 30 30 - Fax: 33 (0) 3 88 41 27 71 - e-mail: cep@edqm.eu
Internet : <http://www.edqm.eu>




30 Manufacture of the substance shall take place in accordance with the Good
31 Manufacturing Practice and in accordance with the dossier submitted.

32 Failure to comply with these provisions will render this certificate void.

33 The certificate is valid provided that there has been no deterioration in the TSE status of
34 the country(ies) of origin of the source material.

35 This certificate is granted within the framework of the procedure established by the
36 European Pharmacopoeia Commission [Resolution AP-CSP (93) 5 as amended] for a
37 period of five years starting from **31 January 2011**. Moreover, it is granted according to
38 the provisions of Directive 2001/83/EC and Directive 2001/82/EC and any subsequent
39 amendment, and the related guidelines.

40 This certificate has one annex of 2 pages.
41 This certificate has:
42 lines.


On behalf of the
Director of EDQM



Strasbourg, 31 January 2011

DECLARATION OF ACCESS *(to be filled in by the certificate holder under their own responsibility)*

DSM Nutritional Products Ltd., as holder of the certificate of suitability

R0-CEP 2009-050-Rev 00 for CHOLECALCIFEROL

hereby authorises Curtis Health Caps Sp. z o.o. Wysogotowo, ul. Batorowska 52 62-081 Przeźmierowo
(name of the pharmaceutical company)

to use the above-mentioned certificate of suitability in support of their application(s) for the following
Marketing Authorisation(s): *(name of product(s) and marketing number(s), if known)*

Protego Witamina D1000 (Y81)

The holder also certifies that no significant changes to the operations as described in the CEP dossier
have been made since the granting of this version of the certificate.

Date and Signature *(of the CEP holder)*:

Dossier for the Certification of Suitability (CEP) to the Monograph of the European Pharmacopoeia [CTD Format – Module 3: Quality]; confidential.

GC-method for the detection and quantification of residual solvents in cholecalciferol.

Determination	
Residual solvents	Methanol, methyl formate, acetone, n-Hexane, pyridine, benzene
Method principle	Gas chromatography using headspace sample preparation and FID detection based on the following parameters
Sample preparation	
Blank solution	Pipet 10.0 ml of dimethylformamide (DMA) into a serum vial and close hermetically.
Standard solutions	In a 100 ml volumetric flask containing a little quantity of DMA (FLUKA HPLC), accurately weigh 90-110 mg of acetone (PROLABO NORMAPUR) and methylformate (MERCK for synthese), 250-350 mg of methanol (PROLABO NORMAPUR), 15-30 mg of n-Hexane (FLUKA PURISS P.A.) and 190-210 mg of pyridine (MERCK P.A.). Bring up to volume with DMA.(= solution 1) Pipet 1.0 ml of solution 1 and dilute to 100.0 ml with DMA (= test solution). Pipet 10.0 ml of the test solution into a serum vial and close hermetically.
Sample Solution	Accurately weigh 0.95 - 1.05 g of product in a serum vial and dissolve with 10.0 ml of DMA. Close hermetically.
Operating procedure	Apply the 'HEADSPACE' method. Place the serum vial in an oven for one hour at 100°C. Inject 1.0 ml of the headspace vapour phase from the vial.
Equipment	
Instrument	Hewlett Packard 6890 series Plus with split/splitless injector
Detector	FID
Temperatures	
a) Column	from 35 °C to 140 °C at 10°C/mn
b) Injector	140 °C
c) Detector	250 °C
Capillary column	length 30 m, internal diameter 0.25 mm, thickness of stationary phase 1.4 µm
Stationary phase	CP-Select 624 CB reference 7412 Chrompack (94%dimethylsiloxane and 6 % cyanopropylphenylsiloxane)
Carrier gas	Helium
Linear velocity of carrier gas	35 cm/s
Split ratio	1/5

3.2.S.4.2 Analytical Procedures [Cholecalciferol, DSM Nutritional Products Ltd., D-Grenzach-Wyhlen/F-Village-Neuf] –

11.02.2009 - RSR



European Directorate for the Quality of Medicines & HealthCare

EDQM CERTIFICATE OF SUITABILITY
CEP No R0-CEP 2009-050-Rev 00
ANNEX 1 p. 1 of 2

Dossier for the Certification of Suitability (CEP) to the Monograph of the European Pharmacopoeia [CTD Format – Module 3: Quality]; confidential.

Integration and calculations	
Retention times	Methanol approximately (\approx) 2.2 min Methyl formate \approx 2.35 min Acetone \approx 3.1 min n-Hexane \approx 3.8 min Pyridine \approx 7.2 min n-Hexane Low fraction \approx 3.4 and \approx 3.6 n-Hexane Low fraction \approx 4.3 and \approx 4.9
Separation time	approx. 16 min
Standardisation	External standardisation.
Calculations	$\mu\text{g} / \text{g} = \frac{S_{\text{Sample}}}{S_{\text{Std}}} \times \frac{P_{\text{Std}} \times 10^3}{100} \times \frac{1}{100} \times 10 \times \frac{1}{P_{\text{Sample}}}$ <p> S_{Sample} area of peak of the considered solvent from the sample solution S_{Std} area of peak of the considered solvent from the standard solution P_{Std} weighed amount of the considered solvent in standard in mg P_{Ech} weighed amount of sample in g 10 and 100 dilution factors 10^3 unit factor (mg to μg) </p>

3.2.S.4.2 Analytical Procedures [Cholecalciferol, DSM Nutritional Products Ltd., D-Grenzach-Wyhlen/F-Village-Neuf] –

11.02.2009 - RSR